Food and Drug Administration perspective: Advancing product development for non-healing chronic wounds.
The US Food and Drug Administration (FDA) understands that innovative product development is essential to addressing the unmet medical need of non-healing chronic wounds. Barriers to product development for non-healing chronic wounds may involve but are not limited to a dearth of biological models,...
| Publicado en: | Wound Repair & Regeneration Vol. 30; no. 3; pp. 299 - 303 |
|---|---|
| Autores principales: | , , , , |
| Formato: | Journal Article |
| Publicado: |
Wiley-Blackwell
May/Jun2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |